BioAge Labs, Inc (BIOA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $255.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
BioAge Labs, Inc (BIOA) Financials: Revenue, Profit and Cash Flow
BioAge Labs reported revenue of $8.99M for the fiscal year ended Dec 31, 2025. That year, net income was -$80.61M with a net margin of -896.1%, operating cash flow was -$81.63M and free cash flow was -$82.35M. The quarter ended Sep 30, 2026 had revenue of $298.00K and net income of -$33.50M.
Revenue and Margins
Over the 12 years to Dec 2025, revenue grew from $2.67M, a compound annual rate of 10.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $8.99M | N/A | 100.0% | -1031.5% | -896.1% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $14.94M | +80.6% | -49.4% | -736.2% | -656.8% |
| Dec 2016 | $8.27M | +280.9% | -65.2% | -358.2% | -271.7% |
| Dec 2015 | $2.17M | +40.8% | -20.3% | -1773.9% | -1713.9% |
| Dec 2014 | $1.54M | -42.1% | -291.7% | -2281.5% | -3008.5% |
| Dec 2013 | $2.67M | N/A | -0.9% | -1545.1% | -1246.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.99M | $0 | $0 | $0 | $14.94M | $8.27M | $2.17M | $1.54M | $2.67M |
| Cost of revenue | $0 | $0 | $0 | N/A | $22.32M | $13.67M | $2.61M | $6.04M | $2.69M |
| Gross profit | $8.99M | $0 | $0 | N/A | -$7.38M | -$5.39M | -$440.83K | -$4.50M | -$23.78K |
| Research and development | $73.97M | $59.04M | $33.89M | $30.52M | $5.47M | $7.20M | $20.29M | $15.16M | $16.58M |
| Operating income | -$92.78M | -$78.19M | -$48.40M | -$39.97M | -$110.01M | -$29.63M | -$38.53M | -$35.20M | -$41.18M |
| Net income | -$80.61M | -$71.11M | -$63.85M | -$39.72M | -$98.15M | -$22.48M | -$37.23M | -$46.42M | -$33.22M |
| EBITDA | N/A | -$78.03M | N/A | -$39.35M | -$88.72M | -$13.29M | -$33.07M | N/A | -$38.84M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $298.00K | $2.45M | $2.77M | $3.08M | $2.05M | $2.41M | $1.45M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $298.00K | $2.45M | $2.77M | $3.08M | $2.05M | $2.41M | $1.45M | N/A | $0 | $0 | $0 | N/A |
| Operating income | -$37.41M | -$29.33M | -$25.38M | -$28.42M | -$23.14M | -$24.77M | -$16.45M | -$25.36M | -$24.75M | -$15.27M | -$12.81M | -$13.60M |
| Net income | -$33.50M | -$26.10M | -$22.25M | -$25.94M | -$20.17M | -$21.56M | -$12.93M | -$21.13M | -$23.41M | -$13.58M | -$12.99M | -$20.96M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $2.65M by $186.24M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $294.89M | $358.23M | $25.92M | $28.43M | $69.51M | $161.33M | $143.09M | $152.44M | $114.08M |
| Current assets | $286.79M | $357.10M | $25.31M | $28.03M | $15.25M | $31.42M | $10.84M | $57.09M | $94.96M |
| Cash and equivalents | $188.89M | $354.35M | $21.64M | $27.64M | $4.63M | $16.16M | $6.97M | $51.04M | $83.73M |
| Total liabilities | $22.84M | $35.11M | $66.60M | $140.99M | $47.66M | $112.84M | $96.73M | $94.91M | $49.07M |
| Short-term debt | $2.65M | $6.00M | $26.67M | $216.00K | $4.92M | $23.30M | $10.30M | $2.98M | $6.52M |
| Long-term debt | $0 | $2.50M | $8.20M | $2.25M | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $272.05M | $323.13M | -$173.40M | -$112.56M | $21.85M | $48.49M | $46.36M | $57.53M | $65.01M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $367.65M | $396.93M | $397.65M | $294.89M | $305.09M | $322.15M | $343.84M | $358.23M | $337.38M | $164.40M | $179.60M | $25.92M |
| Total liabilities | $21.20M | $22.02M | $18.53M | $22.84M | $27.63M | $27.37M | $30.67M | $35.11M | $23.63M | $361.53M | $365.11M | $199.32M |
| Cash and equivalents | $52.67M | $73.96M | $241.78M | $188.89M | $215.57M | $220.33M | $257.49M | $354.35M | $334.47M | $159.09M | $173.99M | $21.64M |
| Shareholder equity | $346.45M | $374.91M | $379.12M | $272.05M | $277.46M | $294.78M | $313.17M | $323.13M | $313.75M | -$197.13M | -$185.51M | -$173.40M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$81.63M | -$51.52M | -$37.36M | -$36.18M | -$29.79M | -$37.62M | -$32.20M | -$22.45M |
| Capital expenditures | $719.00K | $366.00K | $166.00K | $103.00K | $0 | $0 | $0 | $0 |
| Free cash flow | -$82.35M | -$51.89M | -$37.53M | -$36.28M | -$29.79M | -$37.62M | -$32.20M | -$22.45M |
| Share repurchases | $0 | $542.00K | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$95.22M | -$366.00K | -$266.00K | -$103.00K | N/A | N/A | N/A | N/A |
| Financing cash flow | $11.47M | $381.20M | $34.94M | $2.50M | $18.85M | $47.22M | $54.89M | $78.65M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.96M | -$19.26M | -$24.05M | -$28.25M | -$16.04M | -$19.97M | -$17.36M | -$5.14M | -$14.93M | -$15.78M | -$15.67M | -$8.50M |
| Capital expenditures | $18.00K | $328.00K | $26.00K | $112.00K | $22.00K | $159.00K | $426.00K | $26.00K | $305.00K | $35.00K | $0 | $0 |
| Free cash flow | -$30.98M | -$19.59M | -$24.07M | -$28.36M | -$16.07M | -$20.13M | -$17.79M | -$5.16M | -$15.24M | -$15.82M | -$15.67M | -$8.50M |
Frequently Asked Questions About BIOA
What is BioAge Labs' annual revenue?
BioAge Labs reported revenue of $8.99M for the fiscal year ended Dec 31, 2025.
Is BioAge Labs profitable?
No. BioAge Labs reported net income of -$80.61M for the fiscal year ended Dec 31, 2025, with a net margin of -896.1%.
How much free cash flow does BIOA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$81.63M minus capital expenditures of $719.00K produced free cash flow of -$82.35M.
How much debt does BioAge Labs have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $2.65M and cash and equivalents of $188.89M.
What is BIOA's profit margin?
For the fiscal year ended Dec 31, 2025, BioAge Labs reported gross margin of 100.0%, operating margin of -1031.5% and net margin of -896.1%.
BIOA pages: Overview, Earnings, Forecast, Financials, Competitors